株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

2016年までの抗痙攣剤市場:ジェネリック薬による低コストと投与の利便性が新規治療薬の商業的機会を制限

Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies

発行 GBI Research 商品コード 170802
出版日 ページ情報 英文 107 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GBI Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
2016年までの抗痙攣剤市場:ジェネリック薬による低コストと投与の利便性が新規治療薬の商業的機会を制限 Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies
出版日: 2011年01月31日 ページ情報: 英文 107 Pages
概要

てんかん、線維筋痛、片頭痛、神経因性疼痛、双極性障害、不安症など、多くの症状の治療に、ブランド薬および認可外を含め、様々な抗痙攣剤が用いられています。TopamaxやTrileptal、Depakote、Lamictal、Tegretolなどの主流の抗痙攣剤の特許は2007〜2008年に失効しました。様々な症状の管理に抗痙攣剤が用いられることによって、ジェネリック薬が市場に参入し、ジェネリック薬の普及によって、同市場は将来的に衰退すると予測されています。

当レポートでは、世界の抗痙攣剤市場について分析し、地域別市場動向、治療環境、製品パイプライン、市場に参入する企業の競合プロファイル、M&A動向などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 2016年までの抗痙攣剤市場:イントロダクション

第3章 市場概要

  • イントロダクション
  • 世界の抗痙攣剤市場の収益予測

第4章 地域別環境

  • 地域別収益分析
  • 米国
  • 欧州主要5カ国
  • 日本

第5章 治療環境

  • 双極性障害のための抗痙攣剤市場
  • 促進因子と阻害因子
  • 神経因性疼痛のための抗痙攣剤市場
  • 促進因子と阻害因子
  • 線維筋痛のための抗痙攣剤市場
  • 促進因子と阻害因子
  • 片頭痛のための抗痙攣剤市場
  • 促進因子と阻害因子
  • てんかんのための抗痙攣剤市場
  • 促進因子と阻害因子

第6章 製品パイプライン分析

  • イントロダクション
  • 有望薬剤のプロファイル

第7章 競合環境

  • 市場シェア分析
  • Pfizer Inc.
  • UCB Group
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Abbott Laboratories
  • Novartis AG

第8章 M&A環境

  • 2005〜2010年のM&A
  • 2005〜2010年のライセンシング契約
  • 2005〜2010年の共同開発契約

第9章 付録

図表

目次
Product Code: GBIHC070MR

Abstract

GBI Research, the leading business intelligence provider, has released its latest research, “Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies”, which provides insights into global anticonvulsant market and market forecast until 2016.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The report provides an in-depth analysis of the top five therapeutic indications for which often anticonvulsants are prescribed which includes epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder. The report also examines the Global anticonvulsant treatment usage patterns for the covered indication. In addition, the report also includes insights into the anticonvulsant R&D pipeline.

Patent Expiries of the Leading Anticonvulsants Followed by Generics Erosions Will Decline the Anticonvulsants Market by a CAGR of 0.1% in The Future

Various anticonvulsants, both branded and off-label are being used for the treatment of many indications such as epilepsy, fibromyalgia, migraine, neuropathic pain, bipolar disorder and anxiety. The patents of leading anticonvulsants such as Topamax (topiramate), Trileptal (oxcarbazepine), Depakote (divalproex sodium), Keppra (levetiracetam), Lamictal (lamotrigine) and Tegretol (carbamazepine) expired in 2007-2008. The wide applicability of the anticonvulsants for management of the various indications has caused the emergence of generics for these anticonvulsants in the market. This generic erosion will cause decline in the anticonvulsant market in the future.

Strong Anticonvulsants Product Pipeline Will Drive the Anticonvulsant Market in Future

The anticonvulsants product pipeline consists of 23 new molecules in the various stages of clinical trials, as indicated below.

Two anticonvulsants, Fosphenytoin and Stedesa have been filed in the US with FDA and 44% of the total anticonvulsants product pipeline is in Phase III clincal studies. The majority of these molecules are being studied as monotherapies for the treatment of epilepsy.The expected launch of these new anticonvusants in the future is expected to to stabilize the declining anticonvulsant market.

Lyrica Will Be a Market Leader in Anticonvulsants Market in Future

Lyrica (pregabalin) is the branded anriconvulsant product of Pfizer.Lyrica is indicated for the treatment of the epilepsy, fibromyalgia and neuropathic pain. Lyrica along with Neurontin (gabapentin) is the first line of therapy for the treatment of neuropathic pain, especially when tricyclic antidepressants are contraindicated. Lyrica is the only anticonvulsant which has been approved for the treatment of fibromyalgia. Lyrica generated revenue of $2.57 billion and $2.84 billion for Pfizer, in 2008 and 2009 respectively.

The incresing uptake of Lyrica for the treatment of neuropathic pain and fibromyalgia is expected to make Lyrica the market leader in the anticonvusant market in future.

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Anticonvulsants Market to 2016 -Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies”, which provides insights into global anticonvulsant market and market forecast until 2016.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The report provides an in-depth analysis of the top five therapeutic indications for which often anticonvulsants are prescribed which includes epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder. The report also examines the Global anticonvulsant treatment usage patterns for the covered indication. In addition, the report also includes insights into the anticonvulsant R&D pipeline.

GBI Research analysis shows that the overall global anticonvulsant market for the five indications epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder is valued at $7.75 billion in 2009. The market is expected to witness a decline at a CAGR of 0.1% for the forecast period and will reach $7.7 billion by 2016.

Patent expiries of leading anticonvulsant followed by generic erosions are the main reason for decline in anticonvulsant market. However expected launch of new anticonvulsants is expected to stabilize the market in future.

The US was the largest region for the anticonvulsant market in terms of revenue, accounting for 52% followed by Top five countries of Europe and Japan which contributed 36% and 12% respectively.

The top pharmaceutical companies in anticonvulsant market companies - Pfizer, Novartis, Abbott, UCB, Johnson & Johnson and GlaxoSmithKline. Large amount of fragmentation in the market provides significant scope for consolidation through mergers and acquisitions.

Scope

The scope of this report includes -
• Data and analysis on the global anticonvulsant market.
• Annualized market data for the anticonvulsant market from 2002 to 2009, with forecasts to 2016.
• Market data on the therapeutic landscape which covers epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
• Key drivers and restraints that have had a significant impact on the market and on each indication.
• The competitive landscape of the global anticonvulsant market which includes companies such as Pfizer, Novartis, Abbott, UCB, Johnson & Johnson and GlaxoSmithKline.
• Key M&A activities and Licensing Agreements that took place from 2005 to 2010 in the global anticonvulsant market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
• Device a more tailored country strategy through the understanding of key drivers and barriers of the region’s anticonvulsant market.
• Develop key strategic initiatives by understanding the key focus areas and top selling anticonvulsant molecules of leading companies.
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Anticonvulsant Market to 2016 - Introduction

  • 2.1 GBI Research Report Guidance

3. Anticonvulsant Market to 2016 - Market Overview

  • 3.1 Introduction
  • 3.2 Revenue Forecasts for the Global Anticonvulsant Market
    • 3.2.1 Revenue
    • 3.2.2 Annual Cost of Treatment (ACT)

4. Anticonvulsant Market to 2016 - Geographical Landscape

  • 4.1 Revenue Analysis by Geography
  • 4.2 The US
    • 4.2.1 Revenue
    • 4.2.2 Annual Cost of Treatment
  • 4.3 Top Five Countries of Europe
    • 4.3.1 Revenue
    • 4.3.2 Annual Cost of Treatment
  • 4.4 Japan
    • 4.4.1 Revenue
    • 4.4.2 Annual Cost of Treatment

5. Anticonvulsant Market to 2016 - Therapeutic Landscape

  • 5.1 Anticonvulsant Market for Bipolar Disorder
    • 5.1.1 Introduction
    • 5.1.2 Revenue
    • 5.1.3 Annual Cost of Treatment
    • 5.1.4 Treatment Usage Patterns
  • 5.2 Drivers and Barriers to the Anticonvulsant Market for Bipolar Disorder
    • 5.2.1 Drivers for the Bipolar Disorder Market
    • 5.2.2 Barriers for the Disorder Market
  • 5.3 Anticonvulsant Market for Neuropathic Pain
    • 5.3.1 Introduction
    • 5.3.2 Revenue
    • 5.3.3 Annual Cost of Treatment
    • 5.3.4 Treatment Usage Patterns
  • 5.4 Drivers and Barriers to Anticonvulsant Market of Neuropathic Pain
    • 5.4.1 Drivers for Neuropathic Pain Market
    • 5.4.2 Restraints for Neuropathic Pain Market
  • 5.5 Anticonvulsant Market for Fibromyalgia
    • 5.5.1 Introduction
    • 5.5.2 Revenue
    • 5.5.3 Annual Cost of Treatment
    • 5.5.4 Treatment Usage Patterns
  • 5.6 Drivers and Barriers to Anticonvulsant Market of Fibromyalgia
    • 5.6.1 Drivers for the Fibromyalgia Therapeutics Market
    • 5.6.2 Barriers for the Fibromyalgia Therapeutics Market
  • 5.7 Anticonvulsant Market for Migraine
    • 5.7.1 Introduction
    • 5.7.2 Revenue
    • 5.7.3 Annual Cost of Treatment
    • 5.7.4 Treatment Usage Patterns
  • 5.8 Drivers and Barriers to Anticonvulsant Market for Migraine
    • 5.8.1 Drivers for the Migraine Market
    • 5.8.2 Barriers for the Migraine Market
  • 5.9 Anticonvulsant Market for Epilepsy
    • 5.9.1 Introduction
    • 5.9.2 Revenue
    • 5.9.3 Annual Cost of Treatment
    • 5.9.4 Treatment Usage Patterns
  • 5.10 Drivers and Barriers to Anticonvulsant Market for Epilepsy
    • 5.10.1 Drivers to Anticonvulsant Market for Epilepsy
    • 5.10.2 Barriers to Anticonvulsant Market for Epilepsy

6. Anticonvulsant Market to 2016 - Product Pipeline Analysis

  • 6.1 Introduction
    • 6.1.1 Research and Development Pipeline
  • 6.2 Profiles of Promising Anticonvulsant Drugs
    • 6.2.1 Brivaracetam
    • 6.2.2 Clonazepam + Levetiracetam
    • 6.2.3 Epliga
    • 6.2.4 Potiga
    • 6.2.5 USL 255
    • 6.2.6 Vanquix
    • 6.2.7 Trokesa
    • 6.2.8 E2007
    • 6.2.9 Vimpat (Lacosamide)

7. Anticonvulsant Market to 2016 - Competitive Landscape

  • 7.1 Market Share Analysis
  • 7.2 Pfizer Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Business Overview
    • 7.2.3 SWOT Analysis
  • 7.3 UCB Group
    • 7.3.1 Company Overview
    • 7.3.2 Business Overview
    • 7.3.3 SWOT Analysis
  • 7.4 Johnson & Johnson (J&J)
    • 7.4.1 Company Overview
    • 7.4.2 Business Overview
    • 7.4.3 SWOT Analysis
  • 7.5 GlaxoSmithKline plc
    • 7.5.1 Company Overview
    • 7.5.2 Business Overview
    • 7.5.3 SWOT Analysis
  • 7.6 Abbott Laboratories
    • 7.6.1 Company Overview
    • 7.6.2 Business Overview
    • 7.6.3 SWOT Analysis
  • 7.7 Novartis AG
    • 7.7.1 Company Overview
    • 7.7.2 Business Overview
    • 7.7.3 SWOT Analysis

8. Anticonvulsant Market to 2016 - M&A Landscape

  • 8.1 M&A Deals 2005-2010
    • 8.1.1 Deal Summary
    • 8.1.2 Deals by Value
    • 8.1.3 Deals by Geography
  • 8.2 Licensing Deals 2005-2010
    • 8.2.1 Summary of Licensing Deals (2009-2010)
  • 8.3 Co-developments Deals 2005-2010
    • 8.3.1 Summary of Co-development Deals (2009-2010)

9. Anticonvulsants Market to 2016 - Appendix

  • 9.1 Market Definitions
  • 9.2 Abbreviations
  • 9.3 Research Methodology
    • 9.3.1 Coverage
    • 9.3.2 Secondary Research
    • 9.3.3 Primary Research
    • 9.3.4 Expert Panel Validation
  • 9.4 Contact Us
  • 9.5 Disclaimer
  • 9.6 Sources

List of Tables:

  • Table 1: Anticonvulsant Market, Global Revenue of Top Selling Anticonvulsants ($m), Approved Indications, 2007-2009
  • Table 2: Anticonvulsant Market, Future Promising Players in Anticonvulsant Market
  • Table 3: Anticonvulsant Market, Global, Revenue Forecasts ($m), 2001-2009
  • Table 4: Anticonvulsant Market, Global, Revenue Forecasts ($m), 2009-2016
  • Table 5: Anticonvulsant Market, Global, Annual Cost of Treatment ($), 2001-2009
  • Table 6: Anticonvulsant Market, Global, Annual Cost of Treatment ($), 2009-2016
  • Table 7: Anticonvulsant Market, Global, Revenue Analysis by Geography ($m), 2001-2009
  • Table 8: Anticonvulsant Market, Global, Revenue Analysis by Geography ($m), 2009-2016
  • Table 9: Anticonvulsant Market, The US, Revenue ($m) , 2001-2009
  • Table 10: Anticonvulsant Market, The US, Revenue Forecasts ($m), 2009-2016
  • Table 11: Anticonvulsant Market, The US, Annual Cost of Treatment($), 2001-2009
  • Table 12: Anticonvulsant Market, The US, Annual Cost of Treatment ($), 2009-2016
  • Table 13: Anticonvulsant Market, Top Five Countries of Europe, Revenue ($m), 2001-2009
  • Table 14: Anticonvulsant Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2009-2016
  • Table 15: Anticonvulsant Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2001-2009
  • Table 16: Anticonvulsant Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2009-2016
  • Table 17: Anticonvulsant Market, Japan, Revenue ($m), 2001-2009
  • Table 18: Anticonvulsant Market, Japan, Revenue Forecast ($m), 2009-2016
  • Table 19: Anticonvulsant Market, Japan, Annual Cost of Treatment ($), 2001-2009
  • Table 20: Anticonvulsant Market, Japan, Annual Cost of Treatment ($), 2009-2016
  • Table 21: Anticonvulsant Market, Bipolar Disorder, Global, Revenue ($m), 2001-2009
  • Table 22: Anticonvulsant Market, Bipolar Disorder, Global Revenue Forecast ($m), 2009-2016
  • Table 23: Anticonvulsant Market, Bipolar Disorder, Revenue by Geography ($m), 2001-2009
  • Table 24: Anticonvulsant Market, Bipolar Disorder, Revenue by Geography ($m),2009-2016
  • Table 25: Anticonvulsant Market, Bipolar Disorder, Annual Cost of Treatment by Geography ($), 2001-2009
  • Table 26: Anticonvulsant Market, Bipolar Disorder, Annual Cost of Treatment by Geography ($), 2009-2016
  • Table 27: Anticonvulsant Market, Bipolar Disorder, Global Treatment Usage Patterns (Million), 2001-2009
  • Table 28: Anticonvulsant Market, Bipolar Disorder, Global Treatment Usage Patterns (Million), 2009-2016
  • Table 29: Anticonvulsant Market, Neuropathic Pain, Global Revenue ($m), 2001-2009
  • Table 30: Anticonvulsant Market, Neuropathic Pain, Global Revenue Forecast ($m), 2009-2016
  • Table 31: Anticonvulsant Market, Neuropathic Pain, Revenue by Geography, ($m),2001-2009
  • Table 32: Anticonvulsant Market, Neuropathic Pain, Revenue by Geography ($m), 2009-2016
  • Table 33: Anticonvulsant Market for Neuropathic Pain, Global, Annual Cost of Treatment ($), 2001-2009
  • Table 34: Anticonvulsant Market for Neuropathic Pain, Global, Annual Cost of Treatment($), 2009-2016
  • Table 35: Anticonvulsant Market, Neuropathic Pain, Global Treatment Usage Patterns (Million), 2001-2009
  • Table 36: Anticonvulsant Market, Neuropathic Pain, Global Treatment Usage Patterns (Million), 2009-2016
  • Table 37: Anticonvulsant Market, Fibromyalgia, Global Revenue Forecasts ($m), 2001-2009
  • Table 38: Anticonvulsant Market, Fibromyalgia, Global Revenue Forecasts ($m), 2009-2016
  • Table 39: Anticonvulsant Market, Fibromyalgia, Revenue by Geography ($m),2001-2009
  • Table 40: Anticonvulsant Market, Fibromyalgia, Revenue by Geography ($m),2009-2016
  • Table 41: Anticonvulsant Market, Fibromyalgia, Annual Cost of Treatment by Geography ($), 2001-2009
  • Table 42: Anticonvulsant Market, Fibromyalgia, Annual Cost of Treatment by Geography ($), 2009-2016
  • Table 43: Anticonvulsant Market, Fibromyalgia, Treatment Usage Patterns (Million), 2001-2009
  • Table 44: Anticonvulsant Market, Fibromyalgia, Treatment Usage Patterns (Million), 2009-2016
  • Table 45: Anticonvulsant Market, Migraine, Global Revenue Forecasts ($m), 2001-2009
  • Table 46: Anticonvulsant Market, Migraine, Global Revenue Forecasts ($m), 2009-2016
  • Table 47: Anticonvulsant Market, Migraine, Revenue by Geography ($m), 2001-2009
  • Table 48: Anticonvulsant Market, Migraine, Revenue by Geography ($m),2009-2016
  • Table 49: Anticonvulsant Market, Migraine, Global, Annual Cost of Treatment ($), 2001-2009
  • Table 50: Anticonvulsant Market, Migraine, Global, Annual Cost of Treatment ($), 2009-2016
  • Table 51: Anticonvulsant Market, Migraine, Global Treatment Usage Patterns (Million), 2001-2009
  • Table 52: Anticonvulsant Market, Migraine, Global Treatment Usage Patterns (Million), 2009-2016
  • Table 53: Anticonvulsant Market, Epilepsy, Global Revenue Forecasts ($m), 2001-2009
  • Table 54: Anticonvulsant Market, Epilepsy, Global Revenue Forecasts ($m), 2009-2016
  • Table 55: Anticonvulsant Market, Epilepsy, Revenue by Geography, ($m),2001-2009
  • Table 56: Anticonvulsant Market, Epilepsy, Revenue by Geography, ($m),2009-2016
  • Table 57: Anticonvulsant Market for Epilepsy, Global, Annual Cost of Treatment ($), 2001-2009
  • Table 58: Anticonvulsant Market for Epilepsy, Global, Annual Cost of Treatment ($), 2009-2016
  • Table 59: Anticonvulsant Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2001-2009
  • Table 60: Anticonvulsant Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2009-2016
  • Table 61: Anticonvulsant Market, Molecules in Phase III Clinical Trial,2010
  • Table 62: Anticonvulsant Market, Discovery Stage Molecule,2010
  • Table 63: Anticonvulsant Market, Phase I Stage Molecule,2010
  • Table 64: Anticonvulsant Market, Phase II Stage Molecules,2010
  • Table 65: Anticonvulsant Market,, Phase III Stage Molecules,2010
  • Table 66: Anticonvulsant Market, Filed Molecules,2010
  • Table 67: Anticonvulsant Market, Global Major M&A Deals, 2005-2010
  • Table 68: Anticonvulsant Market, Global Licensing Deal, 2005-2010
  • Table 69: Anticonvulsant Market, Global Major Co-developments Deals , 2005-2010

List of Figures

  • Figure 1: Anticonvulsant Market, Global Revenue of Top Selling Anticonvulsant,($m), 2008-2009
  • Figure 2: Anticonvulsant Market, Global, Revenue Forecasts ($m), 2001-2016
  • Figure 3: Anticonvulsant Market, Global, Annual Cost of Treatment ($), 2001-2016
  • Figure 4: Anticonvulsant Market, Global, Revenue Analysis by Geography ($m), 2001-2016
  • Figure 5: Anticonvulsant Market, The US, Revenue Forecasts ($m), 2001-2016
  • Figure 6: Anticonvulsant Market, The US, Annual Cost of Treatment ($), 2001-2016
  • Figure 7: Anticonvulsant Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2001-2016
  • Figure 8: Anticonvulsant Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2001-2016
  • Figure 9: Anticonvulsant Market, Japan, Revenue Forecast ($m), 2001-2016
  • Figure 10: Anticonvulsant Market, Japan, Annual Cost of Treatment ($), 2001-2016
  • Figure 11: Anticonvulsant Market, Bipolar Disorder, Global Revenue Forecasts ($m), 2001-2016
  • Figure 12: Anticonvulsant Market, Bipolar Disorder, Revenue by Geography ($m), 2001-2016
  • Figure 13: Anticonvulsant Market, Bipolar Disorder, Annual Cost of Treatment by Geography ($), 2001-2016
  • Figure 14: Anticonvulsant Market, Bipolar Disorder, Global Treatment Usage Patterns (Million), 2001-2016
  • Figure 15: Anticonvulsant Market, Bipolar Disorder, Global Diseased Population (Million), 2001-2016
  • Figure 16: Anticonvulsant Market, Bipolar Disorder, Global Treatment Seeking Population (Million), 2001-2016
  • Figure 17: Anticonvulsant Market, Bipolar Disorder, Global Diagnosis Population (Million), 2001-2016
  • Figure 18: Anticonvulsant Market, Bipolar Disorder, Global Prescription Population (Million), 2001-2016
  • Figure 19:Anticonvulsant Market, Bipolar Disorder, Global Market Drivers and Barriers, 2009-2016
  • Figure 20: Anticonvulsant Market, Neuropathic Pain, Global Revenue Forecasts ($m), 2001-2016
  • Figure 21: Anticonvulsant Market, Neuropathic Pain, Revenue by Geography ($m), 2001-2016
  • Figure 22: Anticonvulsant Market,Neuropathic Pain, Annual Cost of Treatment ($) by Geography, 2001-2016
  • Figure 23: Anticonvulsant Market,Neuropathic Pain, Global Treatment Usage Patterns (Million), 2001-2016
  • Figure 24: Anticonvulsant Market, Neuropathic Pain, Global Diseased Population (Million), 2001-2016
  • Figure 25: Anticonvulsant Market, Neuropathic Pain, Global Treatment Seeking Population (Million), 2001-2016
  • Figure 26: Anticonvulsant Market,Neuropathic Pain, Global Diagnosis Population (Million), 2001-2016
  • Figure 27: Anticonvulsant Market, Neuropathic Pain, Global Prescription Population (Million), 2001-2016
  • Figure 28: Anticonvulsant Market, Neuropathic Pain, Global Drivers and Barriers, 2009-2016
  • Figure 29: Anticonvulsant Market, Fibromyalgia, Global Revenue Forecasts ($m), 2001-2016
  • Figure 30: Anticonvulsant Market, Fibromyalgia, Revenue by Geography ($m),2001-2016
  • Figure 31: Anticonvulsant Market, Fibromyalgia, Annual Cost of Treatment by Geography ($), 2001-2016
  • Figure 32: Anticonvulsant Market, Fibromyalgia, Treatment Usage Patterns (Million), 2001-2016
  • Figure 33: Anticonvulsant Market, Fibromyalgia, Global Diseased Population (Million), 2001-2016
  • Figure 34: Anticonvulsant Market, Fibromyalgia, Global Treatment Seeking Population (Million), 2001-2016
  • Figure 35: Anticonvulsant Market, Fibromyalgia, Global Diagnosis Population (Million), 2001-2016
  • Figure 36: Anticonvulsant Market, Fibromyalgia, Global Prescription Population (Million), 2001-2016
  • Figure 37: Anticonvulsant Market, Fibromyalgia, Global Market Drivers and Barriers, 2009-2016
  • Figure 38: Anticonvulsant Market, Migraine, Global Revenue Forecasts ($m), 2001-2016
  • Figure 39: Anticonvulsant Market, Migraine, Revenue by Geography, ($m),2001-2016
  • Figure 40: Anticonvulsant Market, Migraine, Global, Annual Cost of Treatment ($), 2001-2016
  • Figure 41: Anticonvulsant Market, Migraine, Global Treatment Usage Patterns (Million), 2001-2016
  • Figure 42: Anticonvulsant Market, Migraine, Global Diseased Population (Million), 2001-2016
  • Figure 43: Anticonvulsant Market, Migraine, Global Treatment Seeking Population (Million), 2001-2016
  • Figure 44: Anticonvulsant Market, Migraine, Global Diagnosis Population (Million), 2001-2016
  • Figure 45: Anticonvulsant Market, Migraine, Global Prescription Population (Million), 2001-2016
  • Figure 46: Anticonvulsant Market, Migraine, Global Market Drivers and Barriers,2009-2016
  • Figure 47: Anticonvulsant Market, Epilepsy, Global Revenue Forecasts ($m), 2001-2016
  • Figure 48: Anticonvulsant Market, Epilepsy, Revenue by Geography ($m), 2001-2016
  • Figure 49: Anticonvulsant Market for Epilepsy, Global, Annual Cost of Treatment ($), 2001-2016
  • Figure 50: Anticonvulsant Market, Epilepsy, Global Treatment Usage Patterns (Million), 2001-2016
  • Figure 51: Anticonvulsant Market, Epilepsy, Global Diseased Population (Million), 2001-2016
  • Figure 52: Anticonvulsant Market, Epilepsy, Global, Treatment Seeking Population (Million), 2001-2016
  • Figure 53: Anticonvulsant Market, Epilepsy, Global, Diagnosis Population (Million), 2001-2016
  • Figure 54: Anticonvulsant Market, Epilepsy, Global, Prescription Population (Million), 2001-2016
  • Figure 55: Anticonvulsant Market, Epilepsy, Global Market Drivers and Barriers, 2009-2016
  • Figure 56: Anticonvulsant Market, Global Product Pipeline by Phase (%), 2010
  • Figure 57: Anticonvulsant Market, Global Top Companies Share (%), 2009
  • Figure 58: Anticonvulsant Market, Global Top Companies Share (%), 2008
  • Figure 59: SWOT Analysis of Pfizer
  • Figure 60: SWOT Analysis of UCB
  • Figure 61: SWOT Analysis of J&J
  • Figure 62: SWOT Analysis of GSK
  • Figure 63: SWOT Analysis of Abbott Laboratories
  • Figure 64: SWOT Analysis of Novartis
  • Figure 65: Anticonvulsant Market, Global Major M&A Deals by Deal Value,($m) 2005-2010
  • Figure 66: Anticonvulsant Market, Global Major M&A Deals by Geography, 2005-2010
  • Figure 67: Anticonvulsant Market, Global, Major Licensing Deals by Geography 2005-2010
  • Figure 68: GBI Research Market Forecasting Model
Back to Top